Grond J, Muller E W, van Goor H, Weening J J, Elema J D
Department of Pathology, University of Groningen, The Netherlands.
Kidney Int. 1988 Feb;33(2):524-9. doi: 10.1038/ki.1988.29.
Administration of puromycin aminonucleoside (PAN) to Wistar rats induces proteinuria and enhanced mesangial deposition of circulating macromolecules. After proteinuria of longer duration focal and segmental glomerular hyalinosis and sclerosis (FSGHS) develops. The present report analyzes these aspects of PAN nephrosis in PVG/c rats, a strain previously shown to be remarkably resistant to proteinuria and FSGHS with aging or after uninephrectomy. In Wistar rats multiple injections of PAN during five months resulted in sustained severe proteinuria and FSGHS lesions in 8.1 +/- 1.0% (mean +/- 1 SEM) of their glomeruli (N = 6). In PVG/c rats a 1.3-fold higher dose of PAN was needed to induce chronic proteinuria similar to the Wistar rats. After five months 3.3 +/- 0.9% of their glomeruli showed FSGHS (N = 6, P less than 0.01) and the glomerular lesions were considerably less advanced. In acute PAN nephrosis induced by a single intravenous injection of PAN the mesangium of Wistar rats contained large amounts of lipid in contrast to a few small mesangial lipid droplets in nephrotic PVG/c rats. After injection of colloidal carbon in nephrotic PVG/c rats no enhanced carbon accumulation was found in the mesangium when compared to nonproteinuric controls. This result clearly differs from the increased mesangial sequestration of circulating material in nephrotic Wistar, and most other rat strains. The unchanged mesangial traficking of macromolecules in nephrotic PVG/c rats and the low incidence of FSGHS lesions in the presence of sustained glomerular proteinuria may reflect a relative resistance to PAN-induced glomerular damage in this particular rat strain.
给Wistar大鼠注射嘌呤霉素氨基核苷(PAN)会诱导蛋白尿,并增加循环大分子在系膜中的沉积。蛋白尿持续较长时间后,会出现局灶节段性肾小球玻璃样变和硬化(FSGHS)。本报告分析了PVG/c大鼠PAN肾病的这些方面,此前已证明该品系在衰老或单侧肾切除后对蛋白尿和FSGHS具有显著抗性。在Wistar大鼠中,五个月内多次注射PAN导致其肾小球出现持续严重蛋白尿和FSGHS病变的比例为8.1±1.0%(平均值±1个标准误)(N = 6)。在PVG/c大鼠中,需要1.3倍更高剂量的PAN才能诱导出与Wistar大鼠相似的慢性蛋白尿。五个月后,其肾小球中有3.3±0.9%出现FSGHS(N = 6,P<0.01),且肾小球病变进展程度明显较轻。在单次静脉注射PAN诱导的急性PAN肾病中,Wistar大鼠的系膜中含有大量脂质,而肾病性PVG/c大鼠的系膜中只有少量小的系膜脂质滴。在肾病性PVG/c大鼠中注射胶体碳后,与非蛋白尿对照组相比,系膜中未发现碳积累增加。这一结果与肾病性Wistar大鼠及大多数其他大鼠品系中循环物质系膜潴留增加明显不同。肾病性PVG/c大鼠中大分子系膜转运未改变,且在持续性肾小球蛋白尿情况下FSGHS病变发生率较低,这可能反映了该特定大鼠品系对PAN诱导的肾小球损伤具有相对抗性。